Table 2.

Change from baseline in bone erosion parameters evaluated by HR-pQCT (full analysis set)

	Month	csDMARDs plus denosumab (N = 21)		csDMARD therapy alone (N = 22)		Difference (csDMARDs plus denosumab − csDMARD therapy alone)
		n	Adjusted mean [95% CI]	n	Adjusted mean [95% CI]	Adjusted mean [95% CI] P value
Bone erosion depth of the 2–3 metacarpal heads, mm	6	17	− 0.46 [− 1.31, 0.39]	25	− 0.20 [− 0.89, 0.49]	− 0.27 [− 0.86, 0.32] P = 0.3486
	12	17	− 0.56 [− 1.41, 0.29]	22	− 0.20 [− 0.90, 0.49]	− 0.35 [− 0.95, 0.24] P = 0.2251
Bone erosion width of the 2–3 metacarpal heads, mm	6	17	− 0.26 [− 1.10, 0.57]	25	− 0.06 [− 0.73, 0.61]	− 0.20 [− 0.81, 0.40] P = 0.4953
	12	17	− 0.27 [− 1.10, 0.56]	22	− 0.03 [− 0.70, 0.64]	− 0.24 [− 0.85, 0.38] P = 0.4364
Bone erosion volume of the 2–3 metacarpal heads, mm3	6	16	− 6.21 [− 23.89, 11.46]	24	− 1.71 [− 16.07, 12.66]	− 4.51 [− 16.67, 7.65] P = 0.4379
	12	17	− 6.25 [− 23.94, 11.44]	21	− 3.18 [− 17.56, 11.20]	− 3.07 [− 15.32, 9.17] P = 0.5979

Data are shown as adjusted mean [95% CI] unless otherwise indicated

n is the number of bone erosions

For adjusted mean, a linear mixed effect model analysis was performed using treatment group, sex, anti-CCP antibody (positive vs negative), baseline DAS28-ESR, measurement time point, and the interaction between the treatment group and measurement time point as fixed effects; patients as random effects; and baseline values as covariates

CCP cyclic citrullinated peptide, CI confidence interval, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, DAS28-ESR Disease Activity Score in 28 joints for rheumatoid arthritis with erythrocyte sedimentation rate as fixed effects, HR-pQCT high-resolution peripheral quantitative computed tomography